+++ Ihre Meinung ist uns wichtig: Wie zufrieden sind Sie mit finanzen.ch? - Hier an unserer Umfrage teilnehmen! +++ -w-
News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
13.10.2019 18:18:00

3 Things Repligen Investors Need to Watch

It may not be as sexy as biopharmaceutical companies developing gene therapies or tailoring the next big cellular medicines, but Repligen (NASDAQ: RGEN) has certainly rewarded investors through its leadership position in bioprocess engineering. The stock has delivered a 10-year return of 1,420%, compared to "only" 238% for the S&P 500 when dividends are included.To be fair, Repligen has earned those epic returns by positioning itself as an indispensable partner for biopharma companies. It develops products and tools that help companies manufacture biological products more safely and efficiently, but it isn't directly linked to the binary risk-reward profile inherent to clinical trials.While the bioprocessing stock has gained 44% since the beginning of 2019 -- including a recent decline -- Repligen has much to look forward to. Here are three things investors will be watching heading into the third-quarter 2019 earnings conference call. (The company hasn't announced the date of the release.)Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Repligen Corp.mehr Analysen

28.08.19 Repligen Outperform First Analysis Securities
22.07.19 Repligen Buy H.C. Wainwright & Co.
26.09.18 Repligen Neutral H.C. Wainwright & Co.

Eintrag hinzufügen

Amun startet mit ETPs in CHF an der BX Swiss | BX Swiss TV

Aktien in diesem Artikel

Repligen Corp. 82.94 1.50% Repligen Corp.

Finanzen.net News